Abstract
Introduction Though uncommon, the collecting duct carcinoma (CDC) of Bellini is a very aggressive primary renal tumour occurring in less than 1% of all renal cell carcinoma (RCC) cases. This rare subtype was always excluded from the prospective trials with targeted therapies. Few data so far available concern the subgroup analyses from the expanded access programs with sorafenib and sunitinib, and from temsirolimus randomized study. Patients and methods From December 2004 to May 2010, 333 patients with advanced RCC have been treated in our Institution with targeted therapies: of these, 7 (2.6%) were affected by CDC. General characteristics, symptoms, pathological features, treatments and patients' outcome were recorded. Results All patients affected by CDC received targeted agents as first-line therapy: more precisely, 4 patients were treated with sorafenib, 2 with temsirolimus and 1 with sunitinib. After progression 2 patients received a secondline treatment with sunitinib. No patients were alive at 5 years. Five patients developed early progression of disease with a very short 4-month survival, while 2 cases had a long-lasting disease control with an overall survival time accounting for 49 and 19 months, respectively. Treatmentrelated adverse events were manageable consisting of fatigue, diarrhoea, hand-foot syndrome, hypertension and anemia, the latter being the most frequent. No treatment discontinuations due to adverse event were needed. Conclusions This investigation shows that targeted agents are safe, displaying some degree of activity in CDCs: therefore, they could be considered as an alternative in patients not eligible to chemotherapy regimens. Further studies including biomarkers as predictive factors of tumour biology and clinical features are required to improve the management of this challenging disease.
| Original language | English |
|---|---|
| Pages (from-to) | 464-467 |
| Number of pages | 4 |
| Journal | Clinical and Experimental Nephrology |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2012 |
Fingerprint
Keywords
- Collecting ducts carcinoma (CDC)
- Nephrectomy
- Renal cell carcinoma (RCC)
- Sorafenib
- Sunitinib
- Targeted therapies
- Temsirolimus
ASJC Scopus subject areas
- Nephrology
- Physiology
- Physiology (medical)
Cite this
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. / Procopio, Giuseppe; Verzoni, Elena; Iacovelli, Roberto; Colecchia, Maurizio; Torelli, Tullio; Mariani, Luigi.
In: Clinical and Experimental Nephrology, Vol. 16, No. 3, 06.2012, p. 464-467.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases
AU - Procopio, Giuseppe
AU - Verzoni, Elena
AU - Iacovelli, Roberto
AU - Colecchia, Maurizio
AU - Torelli, Tullio
AU - Mariani, Luigi
PY - 2012/6
Y1 - 2012/6
N2 - Introduction Though uncommon, the collecting duct carcinoma (CDC) of Bellini is a very aggressive primary renal tumour occurring in less than 1% of all renal cell carcinoma (RCC) cases. This rare subtype was always excluded from the prospective trials with targeted therapies. Few data so far available concern the subgroup analyses from the expanded access programs with sorafenib and sunitinib, and from temsirolimus randomized study. Patients and methods From December 2004 to May 2010, 333 patients with advanced RCC have been treated in our Institution with targeted therapies: of these, 7 (2.6%) were affected by CDC. General characteristics, symptoms, pathological features, treatments and patients' outcome were recorded. Results All patients affected by CDC received targeted agents as first-line therapy: more precisely, 4 patients were treated with sorafenib, 2 with temsirolimus and 1 with sunitinib. After progression 2 patients received a secondline treatment with sunitinib. No patients were alive at 5 years. Five patients developed early progression of disease with a very short 4-month survival, while 2 cases had a long-lasting disease control with an overall survival time accounting for 49 and 19 months, respectively. Treatmentrelated adverse events were manageable consisting of fatigue, diarrhoea, hand-foot syndrome, hypertension and anemia, the latter being the most frequent. No treatment discontinuations due to adverse event were needed. Conclusions This investigation shows that targeted agents are safe, displaying some degree of activity in CDCs: therefore, they could be considered as an alternative in patients not eligible to chemotherapy regimens. Further studies including biomarkers as predictive factors of tumour biology and clinical features are required to improve the management of this challenging disease.
AB - Introduction Though uncommon, the collecting duct carcinoma (CDC) of Bellini is a very aggressive primary renal tumour occurring in less than 1% of all renal cell carcinoma (RCC) cases. This rare subtype was always excluded from the prospective trials with targeted therapies. Few data so far available concern the subgroup analyses from the expanded access programs with sorafenib and sunitinib, and from temsirolimus randomized study. Patients and methods From December 2004 to May 2010, 333 patients with advanced RCC have been treated in our Institution with targeted therapies: of these, 7 (2.6%) were affected by CDC. General characteristics, symptoms, pathological features, treatments and patients' outcome were recorded. Results All patients affected by CDC received targeted agents as first-line therapy: more precisely, 4 patients were treated with sorafenib, 2 with temsirolimus and 1 with sunitinib. After progression 2 patients received a secondline treatment with sunitinib. No patients were alive at 5 years. Five patients developed early progression of disease with a very short 4-month survival, while 2 cases had a long-lasting disease control with an overall survival time accounting for 49 and 19 months, respectively. Treatmentrelated adverse events were manageable consisting of fatigue, diarrhoea, hand-foot syndrome, hypertension and anemia, the latter being the most frequent. No treatment discontinuations due to adverse event were needed. Conclusions This investigation shows that targeted agents are safe, displaying some degree of activity in CDCs: therefore, they could be considered as an alternative in patients not eligible to chemotherapy regimens. Further studies including biomarkers as predictive factors of tumour biology and clinical features are required to improve the management of this challenging disease.
KW - Collecting ducts carcinoma (CDC)
KW - Nephrectomy
KW - Renal cell carcinoma (RCC)
KW - Sorafenib
KW - Sunitinib
KW - Targeted therapies
KW - Temsirolimus
UR - http://www.scopus.com/inward/record.url?scp=84863726660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863726660&partnerID=8YFLogxK
U2 - 10.1007/s10157-012-0589-3
DO - 10.1007/s10157-012-0589-3
M3 - Article
VL - 16
SP - 464
EP - 467
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
SN - 1342-1751
IS - 3
ER -